Ajanta Pharma Completes US FDA Inspection at Maharashtra Facility
Ajanta Pharma Ltd has announced the conclusion of a US FDA inspection conducted at its manufacturing facility located in Paithan, Maharashtra. The inspection took place over a period spanning from April 13, 2026, to April 21, 2026.Upon the conclusion of the inspection, the company received Form-483, which outlined five observations. Ajanta Pharma Ltd stated that the company will respond to the US FDA regarding these findings within the stipulated timeline.
AJANTPHARM Stock Price Movement
On Tuesday, Ajanta Pharma Limited shares gained 0.59%, closing at ₹2791.2. The stock traded on a volume of 138,603 shares, finding support as it finished the day within a range established between ₹2776 and ₹2816.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.